New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 15, 2014
07:34 EDTINCYIncyte duration of response not an issue, says Jefferies
Jefferies says the shorter than expected duration of response for Incyte's '360 with ipilimumab is not an issue since the progression-free survival number is strong. Jefferies believes last night's data suggests that '360 offers up to three times the clinical benefit expected with ipilimumab alone. It maintains a Buy rating on Incyte shares with an $80 price target.
News For INCY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 20, 2014
08:25 EDTINCYIncyte management to meet with UBS
Subscribe for More Information
November 17, 2014
11:06 EDTINCYLeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information
November 13, 2014
13:32 EDTINCYLeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information
13:29 EDTINCYLeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information
13:26 EDTINCYLeerink biotech analysts hold an analyst/industry conference call
Biotech Analysts provide a preview of items being discussed at the upcoming 56th Annual Meeting of ASH including Leukemia/MDS on an Analyst/Industry conference call to be held on November 20 at 10 am.
November 12, 2014
11:17 EDTINCYLeerink major pharma & biotech analysts hold analyst/industry conference call
Subscribe for More Information
November 11, 2014
16:14 EDTINCYLeerink biotech analysts hold an analyst/industry conference call
Biotech Analysts provide a preview of items being discussed at the upcoming 56th Annual Meeting of ASH including JAK inhibitors, novel Jakafi combinations for Myelofibrosis and developing compounds on an Analyst/Industry conference call to be held on November 17 at 10 am.
15:43 EDTINCYLeerink major pharma & biotech analysts hold analyst/industry conference call
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use